The 20th anniversary of the German CLL Study Group and the importance of collaboration
Ruxolitinib plus decitabine in post-MPN AML
Navigating advances in the myeloma landscape over the past couple of years
The importance of BOPA
Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL
John DiPersio et al.